US Patent Issued to Children's Medical Center on Sept. 22 for "Inhibiting the RNA methyltransferase METTL3 or its interaction with EIF3H to suppress oncogene translation and tumorigenesis" (Massachusetts Inventor)

ALEXANDRIA, Va., Sept. 24 -- United States Patent no. 12,742,021, issued on Sept. 22, was assigned to Children's Medical Center Corp. (Boston).

"Inhibiting the RNA methyltransferase METTL3 or its interaction with EIF3H to suppress oncogene translation and tumorigenesis" was invented by Richard I. Gregory (Brookline, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are method of treating cancer using agents that inhibit the interaction between Methyltransferase like 3 (METTL3) and Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3h), and optionally agents that inhibit Bromodomain-containing protein 4 (BRD4). The present disclosure demonstrates the topology of individual polyribosom...